Metra plans to slash costs while seeking new partnerships
This article was originally published in Clinica
Metra Biosystems has announced a plan to significantly reduce its operating expenses next year. The move follows an already reduced cash burn in fiscal 1998 and the company is optimistic that its partnerships with major companies will prompt increased revenue next year. At the end of the last financial year the company had +ACQ-27 million and last year turned in net losses of +ACQ-12 million.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.